Your browser doesn't support javascript.
loading
Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis.
Visser, Marike; Walsh, Kelly; King, Vickie; Sture, Gordon; Caneva, Laura.
  • Visser M; Zoetis VMRD, 333 Portage Street, Kalamazoo, MI, 49007, USA. marike.visser@zoetis.com.
  • Walsh K; Zoetis VMRD, 333 Portage Street, Kalamazoo, MI, 49007, USA.
  • King V; Zoetis VMRD, 333 Portage Street, Kalamazoo, MI, 49007, USA.
  • Sture G; Zoetis VMRD, 333 Portage Street, Kalamazoo, MI, 49007, USA.
  • Caneva L; Zoetis Belgium SA, Rue Laid Burniat 1, 1348, Louvain-La-Neuve, Belgium.
BMC Vet Res ; 18(1): 103, 2022 Mar 17.
Article en En | MEDLINE | ID: mdl-35300697
ABSTRACT

BACKGROUND:

The oral acceptance of oclacitinib maleate (Apoquel®) chewable tablets administered twice daily for 7 days at the labeled dose range of 0.4-0.6 mg/kg was evaluated in 121 dogs treated at ten general practice veterinary clinics in the United States.

RESULTS:

Dogs that were enrolled in the study were client-owned, ranged from 1 to 14 years of age, weighed 3.7 to 60.7 kg, and required twice daily treatment with Apoquel for allergic or atopic dermatitis for 7 days. One hundred and twenty-one (121) dogs with 1673 total dose administrations successfully completed the study and were included in the data summary. Out of a total number of 1673 administrations, 1533 (91.6%) were accepted voluntarily within 5 min, 134 (8%) were consumed with assistance (with food treats or by pilling) outside of the 5 min offering time and 6 (0.4%) doses were not consumed. The per dose percent acceptance rate for the 14 offered doses showed minimal variation ranging from 89.9 to 93.3%.

CONCLUSIONS:

Client-owned dogs from the general veterinary patient population that required treatment with oclacitinib found the chewable tablets to be very palatable and no aversion occurred with repeated dosing. Oclacitinib chewable tablets were well tolerated and are a palatable alternative to the film-coated tablet.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dermatitis Atópica / Fármacos Dermatológicos / Enfermedades de los Perros Límite: Animals País como asunto: America do norte Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dermatitis Atópica / Fármacos Dermatológicos / Enfermedades de los Perros Límite: Animals País como asunto: America do norte Idioma: En Año: 2022 Tipo del documento: Article